Latest Tax Rebates News

Hamelin Gold's December 2024 quarterly report reveals a significant new gold mineralisation zone at the Jazz prospect in the Tanami Province, alongside ongoing exploration advances in the Yilgarn Province and a new tenement application for the Venus project.

West Cobar Metals reports significant resource expansions at its Salazar project alongside promising copper-antimony test results at Bulla Park, while aggressively trimming costs to extend its runway.

Echo IQ Limited has secured FDA clearance for its EchoSolv AS technology and appointed a US-based CEO, marking a pivotal shift towards commercialisation in the American healthcare market.

FBR Limited has successfully completed its US Demonstration Program with CRH Ventures, raising $8 million through a Share Purchase Plan and positioning itself for a significant joint venture in the US construction robotics market.

First Graphene has secured an additional AUD$404,300 R&D tax rebate for significant manufacturing process improvements at its Henderson facility, complementing a recent AUD$166,000 rebate from UK-based research efforts.

Energy Action Limited reports a strong positive operating cash flow of $1.08 million in Q2 FY25, boosted by customer receipts and an R&D tax rebate, while advancing its AI-driven energy platform Utilibox to fuel future growth.

Mont Royal Resources confirms a continuous lithium mineralised zone at its Bohier Lithium Project in Quebec, highlighting promising exploration potential while stepping back from its Wapatik Gold-Copper option.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

Mighty Kingdom Ltd has received $1.809 million in tax rebates, significantly enhancing its capital flexibility as it refines operations and explores future growth opportunities.

EMVision Medical Devices reports strong progress in clinical trials for its emu™ Bedside Scanner, backed by robust cash reserves and strategic non-dilutive funding. The company is poised to commence pivotal FDA validation trials, marking a key step toward commercialisation.

Sparc Technologies has committed to Stage 2 of its hydrogen joint venture, secured a pioneering patent in Morocco, and progressed graphene additive trials, signaling momentum in its clean energy and materials innovation.